



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: CLDX <sup>1</sup>

Last Trade:	0.71
Trade Time:	4:00 PM ET Apr 24, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.65 - 3.42
Volume	N/A
Market Cap. (\$M)	100.301
Shares Out (M)	141.070

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Apr 20, 2018

[Data from Multiple Celldex Programs Presented at American Association for Cancer Research \(AACR\) Annual Meeting 2018](#)

Apr 16, 2018

[Celldex's METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint](#)

Mar 7, 2018

[Celldex Provides Corporate Update and Reports Full Year 2017 Results](#)

Mar 2, 2018

[Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference](#)

Nov 30, 2017

[Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Fourth Quarter Financial Results](#)

Mar 7, 2018

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Definitive Proxy Statement](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)